


 0124
 
 0001
  12
 





The clinical importance of positive results of a DOAC in human urine relates to the presence of DOACs in blood. DOACs are excreted rapidly into urine starting 1 to 2 hours after intake of the medication. A specific and rapid detection indication by a point of care test may support diagnosis of anticoagulant therapy with DOACs especially in emergency medicine. Medical decision-making may be accelerated. Typical indications are patients with ischemic or haemorrhagic stroke with indication for fibrinolytic therapy or administration of a specific antidote, major traumas, emergency procedures, spontaneous thrombotic and bleeding events during oral anticoagulant therapy, and situations without available medication history. The kidney excretes creatinine and DOACs into urine. Their excretion decreases with impairment of renal function. Consequently, DOACs accumulate in blood with decrease of renal function. Therefore, the parameter creatinine was included on the DOAC Dipstick. If creatinine pad shows result „low“, false negative results of DOACs may be detected in urine samples using DOAC Dipstick.

Materials Required but Not Provided
Clean container made of polypropylene for urine sample collection.
Timer.

The test consists of a change of colour upon reaction of Factor Xa or Thrombin on the release of the chromophore bound to a substrate. The release of the chromophore is negatively related to the amount of DOAC in urine. Colours for oral direct Factor Xa and Thrombin inhibitors are different. The colour of the pads on the test strips changes within 10 min and can be identified by naked eye. The colours allow the detection of DOACs in a urine sample, with interpretation as "negative" in the absence of a DOAC and as "positive" in the presence of a DOAC. Respective colours for comparison are printed on the test tube containing the test strips.

Schematic of the DOAC Dipstick

The diagram illustrates the layout of a DOAC Dipstick. It is a vertical strip divided into two main sections. The top section, labeled 'Handling area', is an empty rectangular zone. The bottom section, labeled 'Area with test pads', contains four numbered rectangular pads stacked vertically. Each pad is associated with a specific test function, indicated by a bracket and text to the right of the pad.

Area	Pad Number	Function
Area with test pads	4	Pad 4 for determination of direct oral Thrombin inhibitor
	3	Pad 3 for determination of direct oral Factor Xa inhibitor
	2	Pad 2 for assessing the colour of urine (without reagents)
	1	Pad 1 for determination of Creatinine

Creatinine - The test is based on reaction of creatinine with 3,5-dinitrobenzoic acid in alkaline medium (Benedict-Behre reaction).

Do not use test strips with an expiry date that has already passed.
Carefully read the instructions for use before starting the test.
The instructions must be followed exactly to obtain accurate results.
This test is for professional in vitro diagnostic use only.
Do not touch test pads of the strip. Handle the test strips only at the handling area opposite to the area with the test pads.
Do not open the tube containing the test strips unless you are ready to conduct the test.
Remove only as many test strips as required and reseal the tube immediately with the cap. The cap contains a desiccant.
Perform testing in ambient temperature (20±5°C).

1. Each urine sample must be collected in a clean container made of polypropylene. Only freshly collected urine may be used. If urine samples are collected by urinary catheter, the maximum time between collection in the catheter and testing is two hours.
2. Shake the container lightly before dipping the test strip.
3. Use urine within two hours after collection.

1. Immerse the test strip for 2 to 3 seconds into the urine sample so that all test pads are completely covered by the urine.
2. After removing the test strip from the urine, some liquid may be attached at the borders or edges of the test strips. Wipe off the excess urine on a tissue to absorb runoff. The test pads should not be touched.
3. Place the test strip on a flat surface, so that you can see the test pads, and wait for 10 minutes (incubation time of tests). Use a timer to control the time.
4. After 10 minutes incubation time immediately compare the test pads by naked eye to the corresponding colour scales on the label of the tube container. Refer to the next section regarding the visual determination of the colours.

Colours must be compared to colours of the colour scale printed on the label of the container by naked eye. As an alternative to visually determining the colours of pads 1, 3 and 4, the semi-automatic DOASENSE Reader (DOASENSE REF 0002) can also be used.

- The colour of pad 1 corresponds to colours “**normal**” (“norm.”) on the tube label → creatinine in urine is normal. Pad 3 and pad 4 can be evaluated.
- The colour of pad 1 is darker than the colours “**norm.**” on the tube label → high creatinine does not affect DOAC excretion into urine. Pad 3 and pad 4 can be evaluated.
- The colour of pad 1 is “**low**” or lighter than the respective colour of the tube label → creatinine in urine is low, indicating impairment of renal function. A check of the kidney retention parameters in the patient’s serum should be considered. **Colours of pad 3 and pad 4 may be false negative.**


- The colour of the pad is white as the respective colour marked “**norm.**” on the tube label → the results of pad 1, 3 and 4 are valid.
- The colour of the pad is darker than the colour printed on the tube label → colours of pad 1, pad 3 and pad 4 may be distorted. The test is invalid.

- The colour of pad 3 clearly is yellow as the respective colour marked “**neg.**” on the tube label → direct oral Factor Xa inhibitor is absent in the urine sample.
- The colour of pad 3 is less yellow than the colour marked “**neg.**” on the tube label, and thus the result is “**pos.**” → direct oral Factor Xa inhibitor is present in urine.

- The colour of pad 4 is ochre as the respective colour marked **"neg."** on the tube label → direct oral Thrombin inhibitor is absent in the urine sample.
- The colour of pad 4 is between the ochre colour marked **"neg."** and the rose colour marked **"pos."** on the tube label → direct oral Thrombin inhibitor is present in urine.

present in urine.

If pad 3 and pad 4 are both "pos.", then the test is invalid, because it is unlikely that a person is treated with both types of DOACs.



Creatinine - Reference Range: 0.25 – 3.0 g/l, (2.2 – 26.5 mmol/l) (Ref.: Needleman). Note: The lighter “normal” reference colour for the Creatinine pad on the tube label represents a concentration of 0.25 g/l creatinine in the urine sample.

DOACs - Normal values are below 5 ng/ml (LC-MS/MS method). Patients under DOAC treatment typically display values above 200 ng/ml (Ref.: Schreiner).

The visual analysis of the colours of the DOAC Dipstick corresponds to results "negative" and "positive". The cut off value of Apixaban, Edoxaban, and Rivaroxaban for "negative" is <100 ng/ml, and the cut off value for "positive" is >200 ng/ml. The cut off value of Dabigatran for "negative" is <50 ng/ml and for "positive" >125 ng/ml. In the ranges between the cut off values the colours of the results for the DOACs may be identified as either "negative" or "positive". Data were obtained in artificial urine and normal human urine spiked with concentrations of DOACs ranging from 0 to 1500 ng/ml. Using urine samples of patients treated with Apixaban, Edoxaban, Rivaroxaban, and Dabigatran, sensitivities and specificities were all >95% (Ref.: Harenberg 2020). Concentrations of DOACs in urine are higher due to the lower volume of urine compared to the volume of distribution of DOACs in blood, and were below 5 ng/ml (LC-MS/MS method) in patients not treated with DOACs and typically above 200 ng/ml for all DOACs during treatment and 12 or 24 hours after intake of medication (mean values 5.600 ng/ml Dabigatran, 2.700 ng/ml Rivaroxaban, 1.800 ng/ml Apixaban, n=29 each) (Ref.: Schreiner).

No information is reported in the literature on drug-drug and drug-other compounds interactions in urine – except the coloured compounds in urine described above. The number of interactions tends to be low to very low due to the high specificity of the enzymes with the respective substrates. No interaction occurs between the components of pad 3 with pad 4 and vice versa. Heparins, low-molecular-weight heparins, e.g. enoxaparin, and fondaparinux do not react on pads 3 and 4 (Harenberg 2017). Coloured compounds in urine such as bilirubin, urobilinogen and blood (macrohaematuria) may modify the results of pad 1, pad 3 and pad 4. The impact of the colour of the urine sample can be assessed by pad 2 (see above for interpretation). Creatinine - In urines with high buffering capacity false low reading may be obtained. With high concentrations of ketone bodies (> 50 mmol/l) false normal reading may occur. Blood > 2000 Ery/ul may cause false normal results.

The recommended storage temperature of the closed test-strip tube container is between +2 °C to +30 °C. DOAC Dipsticks may be used until the expiration date printed on the label. After opening, the tube must be closed tightly immediately after removing of the strips used for evaluation, and the closed tube has to be stored away from direct sunlight at temperatures not exceeding +30 °C. Storage above +30 °C will adversely affect the stability and test performance of the product.

Any serious incident in relation to this device shall be reported without any delay to the manufacturer and the national authority of the state in which the user/patient is located.

CLSI. Urinalysis; Approved Guideline - Third Edition. CLSI document GP16-A3; 2009. · Harenberg J et al. *Thromb Haemost* 2020, 120:132-40. · Schreiner R et al. *Res Pract Thromb Haemost* 2017;1(Suppl.1):PB 491. · Harenberg J, et al. *Res Pract Thromb Haemost* 2017;1(Suppl.1):PB 454. · Harenberg J, et al. *Clin Chem Lab Med*. 2016;54:275-83. · Du S, et al. *Clin Chem Lab Med*. 2015;53:1237-47. · Harenberg J, et al. *Semin Thromb Hemost*. 2015;41:228-36. · Favoloro EJ, et al. *Semin Thromb Hemost*. 2015;41:208-27. · Harenberg J, et al. *Thromb J*. 2013 Aug 1;11(1):15. · Needleman SB, et al. *J Forensic Sci*. 1992;37:1125-1133.

 0124	CE Mark - Device complies with European requirements of the IVDR (EU) 2017/746 Regulation	 Lot Number	 Device for near-patient testing
	In Vitro Diagnostics	 Catalogue Number	 Device not for self-testing
	Manufacturer	 Storage Temperature	 Do not reuse
	Content is sufficient for <n> tests	 Expiry Date	 See Instructions for Use

 DOASENSE™ GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany
 Email: info@doasense.de, www.doasense.de